Pharmacogenetics of Vascular Risk Factors in Alzheimer’s Disease

Pharmacogenetics of Vascular Risk Factors in Alzheimer’s Disease

Alzheimer’s disease (AD) is a polygenic/complex disorder in which genomic, epigenomic, cerebrovascular, metabolic, and environmental factors converge to define a progressive neurodegenerative phenotype. Pharmacogenetics is a major determinant of therapeutic outcome in AD. Different categories of gen...

Full description

Bibliographic Details
Main Authors:	Ramón Cacabelos, Arun Meyyazhagan, Juan C. Carril, Pablo Cacabelos, Óscar Teijido
Format:	Article
Language:	English
Published:	MDPI AG 2018-01-01
Series:	Journal of Personalized Medicine
Subjects:	Alzheimer’s disease anti-dementia drugs APOE atorvastatin cholesterol CYP haplotypes Enalapril hypertension LipoEsar pharmacogenetics
Online Access:	http://www.mdpi.com/2075-4426/8/1/3

Similar Items

Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer’s Disease
by: Ramón Cacabelos, et al.
Published: (2021-04-01)

Influence of Metabolic, Transporter, and Pathogenic Genes on Pharmacogenetics and DNA Methylation in Neurological Disorders
by: Olaia Martínez-Iglesias, et al.
Published: (2023-08-01)

Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants
by: Antón Álvarez, et al.
Published: (2010-09-01)

16. Yüzyıl Tezkirelerinde “Eş‘âr” ve “Güftâr” Terimlerinin Şiir Takdimlerindeki Anlam ve İşlevlerine Dair
by: Selim Gök
Published: (2019-12-01)

Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response
by: Rosario D. C. Hirata, et al.
Published: (2011-09-01)

Personalized Management and Treatment of Alzheimer’s Disease
by: Ramón Cacabelos, et al.
Published: (2022-03-01)

Triad of Risk for Late Onset Alzheimer’s: Mitochondrial Haplotype, APOE Genotype and Chromosomal Sex
by: Yiwei Wang, et al.
Published: (2016-10-01)

APOE4 is associated with elevated blood lipids and lower levels of innate immune biomarkers in a tropical Amerindian subsistence population
by: Angela R Garcia, et al.
Published: (2021-09-01)

EFFECT OF GENES SLCO1B1 AND MDR1 POLYMORPHISM ON ATORVASTATIN PHARMACOKINETICS AND PHARMACODYNAMICS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: RESULTS OF PILOT PHARMACOGENETICS STUDY
by: A. V. Semenov, et al.
Published: (2016-01-01)

Pharmacogenetics of lipid diseases
by: Ordovas Jose M
Published: (2004-01-01)

Gene Expression Profiling as a Novel Diagnostic Tool for Neurodegenerative Disorders
by: Olaia Martínez-Iglesias, et al.
Published: (2023-03-01)

CLOPIDOGREL PHARMACOGENETICS
by: A. N. Meshkov
Published: (2016-01-01)

Perspectives of pharmacogenetics approach to personalized tamoxifen therapy
by: M I Savelyeva, et al.
Published: (2017-06-01)

A TOMM40/APOE allele encoding APOE‐E3 predicts high likelihood of late‐onset Alzheimer’s disease in autopsy cases
by: Selma M. Soyal, et al.
Published: (2020-08-01)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Pharmacogenetics of Lethal Opioid Overdose: Review of Current Evidence and Preliminary Results from a Pilot Study
by: Leen Magarbeh, et al.
Published: (2023-05-01)

Principles of pharmacogenetics and pharmacogenomics /
by: Altman, Russ B. 205766, et al.
Published: (2012)

Pharmacogenetic Approaches to Enhancing Efficacy and Safety of Statins as Illustrated by the Example of Atorvastatin
by: R. Ye. Kazakov, et al.
Published: (2020-03-01)

The Correlation of Two Different Real-Time PCR Devices for the Analysis of CYP2C19 Pharmacogenetic Results
by: Alba Alonso Llorente, et al.
Published: (2023-11-01)

Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard
by: Mohammad A. Alshabeeb, et al.
Published: (2022-08-01)

Association of regular glucosamine use with incident dementia: evidence from a longitudinal cohort and Mendelian randomization study
by: Jiazhen Zheng, et al.
Published: (2023-03-01)

Pharmacogenetic Analysis Enables Optimization of Pain Therapy: A Case Report of Ineffective Oxycodone Therapy
by: Florine M. Wiss, et al.
Published: (2023-05-01)

High-Density Lipoprotein Changes in Alzheimer’s Disease Are <i>APOE</i> Genotype-Specific
by: Brian V. Hong, et al.
Published: (2022-06-01)

Pharmacogenetics and phenoconversion: the influence on side effects experienced by psychiatric patients
by: Manon G. den Uil, et al.
Published: (2023-08-01)

Implementation of Pharmacogenetics in First-Line Care: Evaluation of Its Use by General Practitioners
by: Denise van der Drift, et al.
Published: (2023-09-01)

The Progress and Pitfalls of Pharmacogenetics-Based Precision Medicine in Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis
by: Yuxin Teng, et al.
Published: (2023-03-01)

N-Deacetylation of Sinorhizobium meliloti Nod Factors Increases Their Stability in the Medicago sativa Rhizosphere and Decreases Their Biological Activity
by: Christian Staehelin, et al.
Published: (2000-01-01)

High-Affinity Nod Factor Binding Site from Phaseolus vulgaris Cell Suspension Cultures
by: Frédéric Gressent, et al.
Published: (2002-08-01)

White matter injury, cholesterol dysmetabolism, and APP/Abeta dysmetabolism interact to produce Alzheimer’s disease (AD) neuropathology: A hypothesis and review
by: Frank R. Sharp, et al.
Published: (2023-02-01)

Pharmacogenetic Warfarin Dosing Algorithm in the Russian Population
by: T. A. Bairova, et al.
Published: (2019-07-01)

Pharmacogenetics Approach for the Improvement of COVID-19 Treatment
by: Ingrid Fricke-Galindo, et al.
Published: (2021-03-01)

From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice
by: Qamar Shubbar, et al.
Published: (2024-02-01)

Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study
by: Adugna Chala, et al.
Published: (2021-12-01)

Establishment of a Pharmacogenetics Service Focused on Optimizing Existing Pharmacogenetic Testing at a Large Academic Health Center
by: Amy L. Pasternak, et al.
Published: (2020-10-01)

Pharmacogenetics of Drug-Resistant Epilepsy (Review of Literature)
by: Beata Smolarz, et al.
Published: (2021-10-01)

The Influence of the <i>CES1</i> Genotype on the Pharmacokinetics of Enalapril in Patients with Arterial Hypertension
by: Anna Ikonnikova, et al.
Published: (2022-04-01)

Genetic polymorphisms of CYP2B6*6, CYP2C8*3 and CYP2D6*4 in vivax malaria patients from Brazilian Amazon
by: José Pereira de Moura Neto, et al.
Published: (2023-11-01)

Pharmacogenetics of the safety of phenazepam in alcohol withdrawal syndrome: haplotype and combinatorial analyses of polymorphic variants in the pharmacokinetic factor genes
by: D. V. Ivashchenko, et al.
Published: (2020-04-01)

Pharmacogenetics of Donepezil and Memantine in Healthy Subjects
by: María C. Ovejero-Benito, et al.
Published: (2022-05-01)

Impact of LDLR polymorphisms on lipid levels and atorvastatin’s efficacy in a northern Chinese adult Han cohort with dyslipidemia
by: Hong-Liang Zhao, et al.
Published: (2024-04-01)